Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Champions Oncology (CSBR) over the last 15 years, with Q4 2025 value amounting to $22.1 million.

  • Champions Oncology's Total Current Liabilities rose 1739.04% to $22.1 million in Q4 2025 from the same period last year, while for Oct 2025 it was $22.1 million, marking a year-over-year increase of 1739.04%. This contributed to the annual value of $23.9 million for FY2025, which is 1073.3% up from last year.
  • Per Champions Oncology's latest filing, its Total Current Liabilities stood at $22.1 million for Q4 2025, which was up 1739.04% from $22.7 million recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's Total Current Liabilities ranged from a high of $23.9 million in Q2 2025 and a low of $11.2 million during Q1 2021
  • For the 5-year period, Champions Oncology's Total Current Liabilities averaged around $18.4 million, with its median value being $19.5 million (2024).
  • Per our database at Business Quant, Champions Oncology's Total Current Liabilities skyrocketed by 5607.64% in 2022 and then tumbled by 997.14% in 2024.
  • Over the past 5 years, Champions Oncology's Total Current Liabilities (Quarter) stood at $12.5 million in 2021, then soared by 50.31% to $18.7 million in 2022, then increased by 11.82% to $21.0 million in 2023, then dropped by 9.97% to $18.9 million in 2024, then rose by 17.39% to $22.1 million in 2025.
  • Its last three reported values are $22.1 million in Q4 2025, $22.7 million for Q3 2025, and $23.9 million during Q2 2025.